{
    "clinical_study": {
        "@rank": "127809", 
        "acronym": "CLL004", 
        "arm_group": {
            "arm_group_label": "Alemtuzumab", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive Alemtuzumab escalated from initial dose of 3mg/day then 10mg/day and up to 30mg/day  by intravenous infusion(if tolerated). when stable dose of 30mg/day is tolerated, Alemtuzumab is administrated at 30mg by IV infusion 3 times per week for up to 12 weeks (including escalation and stable dose period). After completion of 12 weeks treatment, or discontinuation of treatment within 12 weeks due to disease progression, patients will be visited every 3 months up to 1 year from enrollment or to death, whichever occurs first."
        }, 
        "brief_summary": {
            "textblock": "This is a phase II, prospective, multicenter, open-label study to evaluate the efficacy and\n      safety of Alemtuzumab in patients with relapse and refractory B-cell chronic lymphocytic\n      leukemia."
        }, 
        "brief_title": "Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "B-cell Chronic Lymphocytic Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  An established diagnosis of B-cell chronic lymphocytic leukemia(B-CLL)\n\n          -  Meet criteria of relapsed or refractory CLL\n\n          -  Presence of one or more measurable lesions\n\n          -  ECOG Score 0-1\n\n          -  Life expectancy > 3 months\n\n          -  Female patients with childbearing potential must have a negative serum pregnancy\n             test, male and female patients must agree to use an effective contraceptive method\n             while on study treatment, and for a minimum 1 year following study therapy.\n\n        Exclusion Criteria:\n\n          -  Less than 2 weeks from prior anti-cancer therapy.\n\n          -  Allergic to the antibody or any component of the investigational product.\n\n          -  Other severe, concurrent diseases, including mental disorders, serious cardiac\n             functional capacity (Class III or IV), uncontrolled diabetes.\n\n          -  Use of investigational agents rather than Alemtuzumab.\n\n          -  Active systematic infection or major organ malfunction requiring treatment.\n\n          -  Serum total bilirubin greater than or equal to 1.5 times upper limits of normal; or\n             Serum alanine aminotransferase (ALT) and/or serum aspartate aminotransferase (AST)\n             greater than or equal to 2.5 times upper limits of normal ( no liver metastases); or\n             ALT and/or AST greater than or equal to 5 times upper limits  of normal (liver\n             metastases).\n\n          -  Blood urea nitrogen(BUN) greater than or equal to 1.5 times upper limits of normal or\n             Serum creatinine greater than or equal to 1.5 times upper limits of normal.\n\n          -  White blood cell(WBC) count< 3.5\u00d7109/L or Absolute neutrophil count(ANC)<1.5\u00d7109/L or\n             platelet count<75\u00d7109/L or Hemoglobin<80g/L.\n\n          -  Human immunodeficiency virus (HIV) positive.\n\n          -  Active hepatitis or a history of prior viral hepatitis B or C, or positive hepatitis\n             B serologies without prior immunization.\n\n          -  Pregnant or nursing women.\n\n          -  Known central nervous system(CNS) metastases with B-CLL.\n\n          -  Active secondary malignancy.\n\n          -  cytomegalovirus(CMV) positive or immunodeficiency disease or after stem cell\n             transplantation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982175", 
            "org_study_id": "CMAB004"
        }, 
        "intervention": {
            "arm_group_label": "Alemtuzumab", 
            "description": "Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.\nEscalation to 30mg/day should be accomplished in 3~7 days.\nStable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.\nMore than 30mg daily or 90mg weekly dose is prohibited\n--------------------------------------------------------------------------------", 
            "intervention_name": "Alemtuzumab", 
            "intervention_type": "Biological", 
            "other_name": "Recombinant Humanized Anti-CD52 Mab"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Campath 1G", 
                "Antibodies, Neoplasm", 
                "Alemtuzumab"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Alemtuzumab", 
            "B-cell chronic lymphocytic leukemia", 
            "CD52"
        ], 
        "lastchanged_date": "November 5, 2013", 
        "location": {
            "contact": {
                "email": "zj@bjcancer.org", 
                "last_name": "Jun Zhu, M.D.", 
                "phone": "86-10-88196596"
            }, 
            "facility": {
                "address": {
                    "city": "Peking", 
                    "country": "China", 
                    "state": "Beijing"
                }, 
                "name": "Peking University Cancer Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Open, Prospective, Phase II Study of Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection in Patients With Relapse and Refractory B-cell Chronic Lymphocytic Leukemia", 
        "overall_contact": {
            "email": "lijing@cmablab.org", 
            "last_name": "Jing Li, M.D.", 
            "phone": "86-21-60129260"
        }, 
        "overall_contact_backup": {
            "email": "yanjun@cmablab.org", 
            "last_name": "Jun Yan, M.D.", 
            "phone": "86-21-60129299", 
            "phone_ext": "8629"
        }, 
        "overall_official": {
            "affiliation": "Beijing Cancer Hospital", 
            "last_name": "Jun Zhu, M.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Objective Response Rate was defined as the proportion of patients who have CR, PR during the study as evaluated according to National Comprehensive Cancer Network(NCCN) guideline 2010 response criteria. Response categories include Complete Response(CR) and Partial Response(PR).\nORR=CR+PR", 
            "measure": "Objective Response Rate(ORR)", 
            "safety_issue": "No", 
            "time_frame": "up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982175"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression-Free Survival was defined as the time from randomization to disease progression (PD) or death due to any cause, whichever comes first.", 
                "measure": "Progression-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "description": "Patients were evaluated according to National Comprehensive Cancer Network(NCCN) guideline 2010 response criteria. The best response observed during the study is summarized. Response categories include Complete Response(CR), Partial Response(PR) and Stable Disease(SD).\nDCR=CR+PR+SD", 
                "measure": "Disease Control Rate(DCR)", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "description": "Duration of response was analyzed for patients who achieved a complete release(CR) or partial release(PR) and was defined as the time from the first date of documented response to the date of disease progression or death due to any cause.", 
                "measure": "Duration of Response(DOR)", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "description": "Overall Survival was defined as the duration from randomization to death due to any cause.", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "up to 1 year"
            }, 
            {
                "description": "Analysis of patients with adverse experiences according to CTCAE Version 4.", 
                "measure": "Summary of patients with Adverse Events(AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "up to 1 year"
            }
        ], 
        "source": "Shanghai Zhangjiang Biotechnology Limited Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shanghai Zhangjiang Biotechnology Limited Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}